https://scholars.lib.ntu.edu.tw/handle/123456789/550618
標題: | Current and future aspect of immunotherapy for advanced renal cell carcinoma | 作者: | FU-JEN HSUEH YU-CHIEH TSAI |
公開日期: | 2020 | 出版社: | Wolters Kluwer Medknow Publications | 卷: | 31 | 期: | 1 | 起(迄)頁: | 8-14 | 來源出版物: | Urological Science | 摘要: | Renal cell carcinoma (RCC) has been recognized as a cancer responsive to the activation of the immune system. In the 1980s, interferon-alpha and interleukin-2 were shown to prolong survival, but they were not widely used due to toxicities. Then, vascular endothelial growth factor receptor and mammalian target of rapamycin inhibitors demonstrated clinical benefits and became the principal treatment in the first- and second-line setting of metastatic RCC (mRCC). In recent years, the efficacy of immune checkpoint inhibitors (ICIs) is confirmed, either alone or in combination with ICI or antiangiogenic agents. ICI-based immunotherapies have now changed the landscape of treatment of mRCC. In this article, we will review the progress of immunotherapy in clear-cell mRCC. ? 2020 Iranian Journal of Nursing and Midwifery Research - Published by Wolters Kluwer -Medknow. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080888765&doi=10.4103%2fUROS.UROS_77_19&partnerID=40&md5=0e169940ea3cda198f2d3b66ddce63a9 https://scholars.lib.ntu.edu.tw/handle/123456789/550618 |
ISSN: | 1879-5226 | DOI: | 10.4103/UROS.UROS_77_19 | SDG/關鍵字: | alpha interferon; angiogenesis inhibitor; antineoplastic agent; atezolizumab; avelumab; axitinib; bevacizumab; cytotoxic T lymphocyte antigen 4; interleukin 2; ipilimumab; nivolumab; pembrolizumab; programmed death 1 ligand 1; vasculotropin; advanced cancer; cancer combination chemotherapy; cancer immunotherapy; human; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; randomized controlled trial (topic); renal cell carcinoma; Review |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。